Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.55 |
| ▸ | GABRP | O00591 | 2/20 | 0.47 |
| ▸ | GABRD | O14764 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.47 |
| ▸ | GABRE | P78334 | 2/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337353 | 0.81 | GPR3 (0.57) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL27979888 | 0.79 | GPR3 (0.55) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL23373487 | 0.78 | GPR3 (0.53) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL16625724 | 0.77 | GPR3 (0.52) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3333405 | 0.77 | GPR3 (0.52) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL27899830 | 0.76 | GPR3 (0.50) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL27979684 | 0.76 | GPR3 (0.50) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3423941 | 0.75 | GPR3 (0.80) | GPR3KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL2216224 | 0.74 | KDM4E (0.59) | GPR3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL12938257 | 0.74 | GPR3 (0.48) | GPR3GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | claimed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | claimed |
| EP-2125812-B2 | USE OF ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX LTD (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | disclosed |
| EP-2125812-B1 | USE OF ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX LTD (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | disclosed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | disclosed |
| WO-2008104161-A1 | ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX LTD. (DE) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, SNCA, CHAT | GPR3 208/4885GABRP 1512/4885GABRD 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.